Regenerative cell therapy biotech uses IPO to blast into human trials
PharmaVoice
JUNE 5, 2024
Bucking conventional fundraising, FibroBiologics’ CEO Pete O’Heeron explains why the biotech company bet on themselves in the public market.
Wed.Jun 05, 2024
297 
Increased Social Vulnerability Accounted for Decrease in Diabetes Control
Drug Topics
JUNE 5, 2024
In an abstract presented at the Endocrine Society’s ENDO 2024 annual meeting in Boston, Massachusetts, researchers addressed the association between social vulnerability and glycemic control in patients with diabetes.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Researchers Find Shared Multiomic Molecular Dysregulations in Brains With PTSD and MDD
Pharmacy Times
JUNE 5, 2024
The investigators are optimistic that the data can establish stress-related pathways while revealing potential therapeutic options for patients with major depressive disorder and post-traumatic stress disorder.
Examining Excessive Weight Gain, Impact of High Insulin Levels in Breast Cancer
Drug Topics
JUNE 5, 2024
Posters presented at ENDO 2024 investigated excessive weight gain in breast cancer survivors and how high insulin levels impact outcomes for Black women with an aggressive form of the disease.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Finland to offer bird flu vaccine to select groups of people, a possible global first
STAT
JUNE 5, 2024
LONDON — Finland is preparing to offer vaccines to people at risk of exposure to an avian influenza strain spreading among farmed and wild animals, health officials there said, potentially becoming the first country to take such a step as concerns about the threat the virus poses to people intensify. The vaccine campaign will be limited, with doses set to be available to groups including poultry farmers, veterinarians, scientists who study the virus, and people who work on fur farms housi
Migraine and Headache Awareness Month: Resources Roundup
Drug Topics
JUNE 5, 2024
Check out this list of resources to share with patients who are managing a migraine or other headache diagnosis.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
Pre-, Probiotics May Improve Patient Quality of Life During Immunotherapy
Drug Topics
JUNE 5, 2024
Study results were promising, but larger studies are needed.
STAT+: Eli Lilly’s obesity drug Zepbound improved liver scarring in mid-stage MASH study
STAT
JUNE 5, 2024
Eli Lilly’s blockbuster diabetes and obesity drug improved living scarring in a mid-stage study of the liver disease MASH, adding to positive data announced earlier this year. The study tested three doses of tirzepatide, sold commercially as Mounjaro or Zepbound. The percentage of patients who experienced a greater than one-stage improvement in scarring, or fibrosis, without worsening of their disease was 54.9%, 51.3%, and 51.0% from the lowest to highest doses.
FDA Advisory Panel Votes Against MDMA-Assisted Therapy for PTSD
Drug Topics
JUNE 5, 2024
The Psychopharmacologic Drugs Advisory Committee voted 10-1 that the benefits of MDMA do not outweigh its potential risks.
Opinion: 100,000 models show that not much was learned about stopping the Covid-19 pandemic
STAT
JUNE 5, 2024
In the midst of the Covid-19 pandemic, scientists and public health institutions made bold claims about the effectiveness of various policy responses such as closing schools and banning public gatherings. These claims shaped government responses and had enormous effects on the lives of billions of people around the world. Are those claims supported by data?
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Study: Tezepelumab Reduces Annual Rates of Exacerbations Related to COPD
Pharmacy Times
JUNE 5, 2024
For patients with a blood eosinophil count of 150 cells/µL or greater, tezepelumab had a significant reduction of approximately 37% in the rate of moderate or severe exacerbations.
STAT+: Student group that ranked med schools over industry conflicts votes to accept pharma funding
STAT
JUNE 5, 2024
An organization devoted to educating future doctors about conflicts of interest will now accept industry funding due to financial stress, prompting outrage from former members who argue the decision will undermine its mission. In a little-noticed move, the American Medical Student Association board recently approved an emergency resolution to accept money from drug and device makers, as well as health insurers, so long as funding does not exceed 25% of its operating budget.
Poor Cardiovascular Health in Women Linked to Cognitive Decline in Midlife
Pharmacy Times
JUNE 5, 2024
Data show women with poor cardiovascular health may have an increased risk of early signs of cognitive decline in midlife.
STAT+: Gilead to pay $40 million to settle claims it delayed newer HIV treatment to boost profits
STAT
JUNE 5, 2024
Gilead Sciences agreed in principle to pay $40 million to more than 2,600 AIDS patients who claimed the company boosted profits by marketing an HIV drug without disclosing harmful side effects while delaying development of a safer alternative treatment. The agreement caps a dispute that cast a harsh spotlight on a strategy that Gilead allegedly used to maximize revenues and extend the lifespan of a best-selling product, but at the expense of patients.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Study: Prevalence of Diabetes Expected to Increase by 59.7% in 2025
Pharmacy Times
JUNE 5, 2024
Body mass index is the main driver of type 2 diabetes globally, accounting for 52.2% of disability-adjusted life years.
Withdrawal symptoms hit one in six patients stopping antidepressants, review finds
STAT
JUNE 5, 2024
The moment when a person stops taking their antidepressant is fraught. Not only can patients see their psychiatric symptoms return, but they can experience a wide variety of new symptoms in the days and weeks immediately following the medication change. Symptoms like nausea and headache can be manageable, and typically begin and end within days of ending the medication.
Appeals court upholds ruling barring former Express Scripts chief from joining CVS
Fierce Healthcare
JUNE 5, 2024
A federal appeals court has upheld an injunction preventing the former head of Express Scripts from taking an executive role at CVS Health. | A federal appeals court has upheld an injunction preventing the former head of Express Scripts from taking an executive role at CVS Health.
STAT+: As Washington mulls new AI rules, startup leaders want a seat at the table
STAT
JUNE 5, 2024
WASHINGTON — In San Francisco, Y Combinator’s firebrand chief executive Garry Tan is one of the startup economy’s most recognizable figures. Well before he became the leader of the coveted startup accelerator that bred global brands like Airbnb, Stripe and OpenAI, Tan was a self-made founder who sold his own company to Twitter. But here in the nation’s political capital, Tan is far less known.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Educate Caregivers About Proper OTC Cold and Cough Medications for Children
Pharmacy Times
JUNE 5, 2024
Approximately 40% of caregivers make dosing errors when administering liquid medication to children.
STAT+: Appeals court overturns Sutter Health’s victory in $400 million antitrust case
STAT
JUNE 5, 2024
When Sutter Health was on trial for anticompetitive conduct in 2022, the San Francisco jury missed out on some crucial details. They didn’t hear, for example, how its former finance chief said the system would make an extra $200 million per year by making insurers contract with all of its hospitals instead of just a few. Or how its former CEO said, “Related to the health plans, we force them to pay us more.
Coverage pathways for psychedelic therapies
Fierce Healthcare
JUNE 5, 2024
This week on "Podnosis," we explore therapeutic psychedelics. | This week on "Podnosis," we explore therapeutic psychedelics. Noah Tong from Fierce Healthcare sat down with Kim Chew, Senior Counsel at Husch Blackwell, to discuss the accessibility challenges in this promising but complex space.
Opinion: As states legalize recreational marijuana use for adults, they must prioritize protecting kids
STAT
JUNE 5, 2024
Thirty-eight states and the District of Columbia have legalized the use of marijuana products for medical use, and 24 of those have legalized it for adult recreational use. As states establish their legal marijuana markets, their main priority — before addressing concerns around tax revenue, social equity issues, illegal markets, or anything else — should be ensuring that young people are protected from exposure to marijuana and can’t access it.
First rare disease therapies chosen for FDA START programme
pharmaphorum
JUNE 5, 2024
An initiative set up by the FDA to accelerate the development of therapies for rare disease in the same way that Operation Warp Speed delivered COVID-19 vaccine has chosen its first pilot programme candidates.
Judge denies FTC's preliminary bid to block Novant, CHS' $320M hospital deal
Fierce Healthcare
JUNE 5, 2024
Novant Health and Community Health Systems (CHS) will be permitted to consummate their contested $320 million hospital deal, though the pair still face some regulatory uncertainty following the dea | U.S. District Judge Kenneth Bell wrote that the two-hospital transaction has "at least as much likelihood of competitive benefits as it does competitive harm.
ASCO: KRAS upstarts set their sights on NSCLC market
pharmaphorum
JUNE 5, 2024
KRAS inhibitors from Eli Lilly, Genfleet, and InxMed make their case for use in NSCLC at ASCO, as they case down Amgen and Bristol-Myers Squibb's market drugs
Appeals court revives $411M antitrust class action against Sutter Health
Fierce Healthcare
JUNE 5, 2024
An appellate court panel has resuscitated a nine-figure antitrust class-action lawsuit against Sutter Health, ruling Tuesday that a 2022 jury was given improper instructions and that a new trial mu | The decadelong case had been unanimously ruled in the nonprofit system's favor back in 2022. A 2-1 panel has now reversed the judgment and remanded for a new trial.
STAT+: FTC loses its bid to block Novant’s hospital merger in North Carolina
STAT
JUNE 5, 2024
A federal judge ordered Wednesday that Novant Health can move forward with its plan to buy two North Carolina hospitals, denying the Federal Trade Commission’s request for an injunction. The FTC sued to block the deal in January, arguing that it would give Novant control of more than 65% of the region’s inpatient market. The case, one seeking to block nearby hospitals from merging and creating an even more powerful dominant player, is the FTC’s bread and butter.
PHTI backs virtual therapies for musculoskeletal disorders
pharmaphorum
JUNE 5, 2024
PHTI's latest report finds that digital therapies for musculoskeletal conditions like low back pain can deliver clinically meaningful benefits
Bristol Myers puts more than 860 jobs on chopping block in NJ as $1.5B savings campaign rolls ahead
Fierce Pharma
JUNE 5, 2024
The scope of Bristol Myers Squibb’s $1.5 billion savings drive is beginning to come into focus. | Starting this month, BMS will begin the process of laying off around 863 employees in Lawrenceville, New Jersey, according to a Worker Adjustment and Retraining Notification (WARN) alert from the state. The move forms part of BMS’ campaign to shave off $1.5 billion in costs by the end of 2025, a company spokesperson said over email.
Gilead, Ipsen build the case for their PBC drugs at EASL
pharmaphorum
JUNE 5, 2024
Gilead Sciences is just a few weeks away from an FDA decision on seladelpar for rare liver disease primary biliary cholangitis (PBC) and will be buoyed by new data pointing to its long-term efficacy and safety.
STAT+: Pharmalittle: We’re reading about MDMA ‘no’ votes, a Gilead settlement, and more
STAT
JUNE 5, 2024
Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far, so we are determined to hang on for another couple of days. And why not? The alternatives — at least those we can identify — are not so appetizing. And what better way to make the time fly than to keep busy.
When is the best time to take milk thistle?
The Checkup by Singlecare
JUNE 5, 2024
Milk thistle ( Silybum marianum ) is a tall plant with purple flowers that belongs to the daisy family. Originally native to Europe, milk thistle can now be found all over the world. The plant’s main active ingredient, an antioxidant called silymarin , is responsible for many of the health benefits of milk thistle. Because of this, milk thistle and silymarin are often used interchangeably to refer to the same plant.
Testing begins for a new form of PrEP
STAT
JUNE 5, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Jason Mast here filling in for Elaine. We’ve got a dramatic vote on psychedelic therapy, record drug shortages, bad (maybe?) news for Biomarin, and a new kind of PrEP.
Let's personalize your content